IL7R and hematopoietic and lymphoid cell neoplasm: Furthermore, activation of IL7Rα and γc heterodimeric complex stimulates JAK3‐STAT5 signaling pathway, driving hematological cancer development,32 implicating therapeutic relevance of IL7R as a therapeutic target.33